Abbott Laboratories (NYSE:ABT) Shares Purchased by Sei Investments Co.

Sei Investments Co. grew its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 0.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 853,482 shares of the healthcare product maker's stock after purchasing an additional 4,430 shares during the period. Sei Investments Co.'s holdings in Abbott Laboratories were worth $96,537,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Cape Investment Advisory Inc. lifted its holdings in Abbott Laboratories by 6.6% in the fourth quarter. Cape Investment Advisory Inc. now owns 1,236 shares of the healthcare product maker's stock valued at $140,000 after acquiring an additional 76 shares during the period. Cyrus J. Lawrence LLC lifted its stake in shares of Abbott Laboratories by 9.0% in the fourth quarter. Cyrus J. Lawrence LLC now owns 954 shares of the healthcare product maker's stock valued at $107,000 after purchasing an additional 79 shares during the period. LMG Wealth Partners LLC grew its position in Abbott Laboratories by 3.8% during the fourth quarter. LMG Wealth Partners LLC now owns 2,161 shares of the healthcare product maker's stock worth $244,000 after buying an additional 80 shares during the period. Jacobson & Schmitt Advisors LLC increased its holdings in Abbott Laboratories by 2.9% in the fourth quarter. Jacobson & Schmitt Advisors LLC now owns 2,827 shares of the healthcare product maker's stock valued at $320,000 after buying an additional 80 shares in the last quarter. Finally, Glass Wealth Management Co LLC lifted its position in shares of Abbott Laboratories by 3.2% during the 4th quarter. Glass Wealth Management Co LLC now owns 2,640 shares of the healthcare product maker's stock valued at $299,000 after acquiring an additional 81 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Abbott Laboratories Trading Up 0.7 %

NYSE:ABT traded up $0.86 during trading hours on Wednesday, reaching $126.46. 6,053,463 shares of the company were exchanged, compared to its average volume of 5,470,513. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23. The stock has a 50 day simple moving average of $129.35 and a 200 day simple moving average of $120.16. The firm has a market cap of $219.31 billion, a price-to-earnings ratio of 16.53, a PEG ratio of 2.52 and a beta of 0.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.34. The firm had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.19 earnings per share. As a group, analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.87%. Abbott Laboratories's dividend payout ratio (DPR) is 30.85%.

Analysts Set New Price Targets

Several research firms recently weighed in on ABT. Wells Fargo & Company raised their price objective on Abbott Laboratories from $133.00 to $136.00 and gave the company an "overweight" rating in a research note on Thursday, January 23rd. Barclays reaffirmed an "overweight" rating and set a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. StockNews.com downgraded shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 12th. Stifel Nicolaus upped their price target on shares of Abbott Laboratories from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Finally, Evercore ISI raised their price objective on shares of Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a research note on Thursday, January 2nd. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $137.94.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. This represents a 15.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the transaction, the executive vice president now directly owns 71,928 shares in the company, valued at approximately $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 116,449 shares of company stock worth $15,463,316 over the last ninety days. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.